What is the difference between acalatinib/acalabrutinib capsules and tablets?

Acalabrutinib/Acalabrutinib is currently on the market in capsule formulations and tablets. The tablet formulation was developed so that patients who need to take gastric acid reduction drugs can also take acalabrutinib. It is expected that the safety and effectiveness of acalabrutinib tablets are the same as acalabrutinib capsules.

Acotinib is a targeted BTK inhibitor therapy that can be used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It can also be used to treat previously treated mantle cell lymphoma (MCL). These conditions are considered incurable chronic diseases. No treatment can permanently get rid of CLL, SLL, and MCL. However, doctors can prescribe medications to help reduce the risk of the condition growing or spreading, and one of its treatment options may be targeted therapy.

Acotinib tablets are an improved formulation compared to acotinib capsules. Because the tablets can be taken with the acid reducer or alone, more cancer patients can benefit. Dissolution standards for a drug are determined based on all available information on the safety, efficacy, and in vitro performance of the drug. The drug strength and dose of acotinib will remain unchanged at 100 mg taken orally twice daily, approximately every 12 hours, with or without food.

Acotinib tablets and capsules should not be taken together or interchanged. Capsules can still be taken until used up. If you are still taking capsules, continue to avoid taking proton pump inhibitors (such as omeprazole, etc.). Acotinib capsules should be taken within 2 hours before taking H2-receptor antagonists (such as famotidine) and within 2 hours before or after taking antacids (such as omeprazole).